Tubulins - the target for anticancer therapy

Curr Top Med Chem. 2015;15(1):73-82. doi: 10.2174/1568026615666150112115805.

Abstract

Tubulin has picked up great focus as a major target in drug discovery and consequently, tubulin inhibitors have pulling in a considerable attention as anticancer agents. Numerable naturally occurring agents have focused on tubulin system act as an imperative target of cancer chemotherapy. Substantial number of tubulin inhibitors has been discovered so far and these agents are classified as indicated by their interaction. They are colchicine site binder, vinca- alkaloid related drugs and those interacting with the Taxol binding site and functioning as stabilising agents. We review the recent advances in the advancement of tubulin interfering agents and will render the current trend in the improvement of tubulin inhibitors as anticancer agents.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Phytogenic / chemistry*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Binding Sites
  • Chalcones / chemistry
  • Chalcones / therapeutic use
  • Clinical Trials as Topic
  • Colchicine / chemistry
  • Colchicine / therapeutic use
  • Humans
  • Macrolides / chemistry
  • Macrolides / therapeutic use
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Paclitaxel / chemistry
  • Paclitaxel / therapeutic use
  • Protein Binding
  • Structure-Activity Relationship
  • Tubulin / chemistry*
  • Tubulin Modulators / chemistry*
  • Tubulin Modulators / therapeutic use
  • Vinca Alkaloids / chemistry
  • Vinca Alkaloids / therapeutic use

Substances

  • Antineoplastic Agents, Phytogenic
  • Chalcones
  • Macrolides
  • Tubulin
  • Tubulin Modulators
  • Vinca Alkaloids
  • Paclitaxel
  • Colchicine